PD-1 / PD-L1
Os inibidores de PD-1/PD-L1 são inibidores de checkpoints imunológicos que bloqueiam a interação entre a proteína de morte celular programada 1 (PD-1) nas células T e seu ligante PD-L1 nas células cancerígenas. Essa interação normalmente suprime a resposta imunológica e permite que as células cancerígenas evitem a detecção imunológica. Ao inibir PD-1/PD-L1, esses inibidores aumentam a capacidade do sistema imunológico de reconhecer e destruir células cancerígenas, induzindo apoptose e regressão tumoral. Os inibidores de PD-1/PD-L1 são fundamentais na pesquisa em imunoterapia e no tratamento do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de PD-1/PD-L1 de alta qualidade para apoiar sua pesquisa em imunooncologia, apoptose e terapia do câncer.
Se han encontrado 125 productos de "PD-1 / PD-L1"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Sotiburafusp alfa
CAS:<p>Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connected</p>Pureza:98%Forma y color:SolidN-deacetylated BMS-202
CAS:<p>N-deacetylated BMS-202 is an inhibitor of PD-1/PD-L1 interaction with potential anticancer activity for cancer research.</p>Fórmula:C23H27N3O2Pureza:98.13% - 98.13%Forma y color:SolidPeso molecular:377.48BMS-8
CAS:<p>BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.</p>Fórmula:C27H28BrNO3Pureza:98.88%Forma y color:SolidPeso molecular:494.42BMS-1166
CAS:<p>BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor.</p>Fórmula:C36H33ClN2O7Pureza:99.22%Forma y color:SolidPeso molecular:641.11Nivolumab
CAS:<p>Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity. Cost-effective and quality-assured.</p>Pureza:98% - 98%Forma y color:LiquidPeso molecular:146 kDaPembrolizumab
CAS:<p>Pembrolizumab (MK-3475) is a humanized monoclonal antibody.Cost-effective and quality-assured.</p>Pureza:95% - 99.70%Forma y color:LiquidPeso molecular:149 kDaBMS-1001
CAS:<p>BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).</p>Fórmula:C35H34N2O7Pureza:98.43%Forma y color:SolidPeso molecular:594.7Avelumab
CAS:<p>Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity.</p>Pureza:95% - 97.17% (SDS-PAGE)Forma y color:LiquidPeso molecular:143.8 kDaARB-272572
CAS:<p>ARB-272572 is a PD-L1 signaling inhibitor that produces immunostimulatory activity in human primary cells.</p>Fórmula:C32H36N6O4Pureza:97.36% - 98.07%Forma y color:SolidPeso molecular:568.67Socazolimab
CAS:<p>Socazolimab (ZKAB001) is a monoclonal antibody targeting PD-L1 with antitumor activity, used in studies of recurrent or metastatic cervical cancer.</p>Pureza:95%Forma y color:LiquidEnvafolimab
CAS:<p>Envafolimab (ASC 22) is a humanized antibody targeting PD-L1, with anticancer activity, blocking the PD-L1 and PD-1 interaction.</p>Pureza:95%Forma y color:LiquidBMS-1166-N-piperidine-CO-N-piperazine dihydrochloride
CAS:<p>BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride is a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1)/programmed cell death ligand 1 (</p>Fórmula:C41H45Cl3N4O5Pureza:98.94%Forma y color:SoildPeso molecular:780.18Ivonescimab
CAS:<p>Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, NSCLC).</p>Pureza:95% - 95%Forma y color:LiquidAcasunlimab
CAS:<p>Acasunlimab (GEN1046) is a bsAb that targets PD-L1 and 4-1BB, boosting T/NK cells and blocking PD-1/PD-L1 in cancer research.</p>Forma y color:LiquidReozalimab
CAS:<p>Reozalimab (LY3434172) is a bispecific monoclonal antibody targeting PD-1/PD-L1, antitumour and enhances T-cell activation in vitro.</p>Pureza:95% - 95%Forma y color:LiquidPeresolimab
CAS:<p>Peresolimab is a humanized antibody targeting PD-1, potentially stimulating immune inhibitory pathways for autoimmune disease research.</p>Pureza:95% - 95%Forma y color:LiquidVisugromab
CAS:<p>Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15.</p>Pureza:95% - 95%Forma y color:LiquidGilvetmab
CAS:<p>Gilvetmab is a caninized anti-PD-1 antibody approved for veterinary use, researched for stage I-III mast cell tumors and stage II-III melanoma in dogs.</p>Pureza:95% - 95%Forma y color:LiquidRulonilimab
CAS:<p>Rulonilimab, a human IgG1 monoclonal antibody, inhibits PD-1 to enhance immune response and exhibit anti-tumor effects.</p>Forma y color:LiquidRosnilimab
CAS:<p>Rosnilimab is a PD-1 agonist that inhibits T cell proliferation and depletes T cells, enabling research into inflammatory diseases.</p>Pureza:95% - 95%Forma y color:Liquid
